高脂血症患者LDL氧化易感性及调脂药物干预的影响(英文)

The Oxidative Susceptibility of Low-density Lipoprotein in Hyperlipidemic Patients and the Role of Lipid-regulating Drugs

目的 观察高脂血症对LDL氧化易感性的影响以及调脂药物干预后的改变。方法 应用短程密度梯度超速离心分离血浆LDL ,对 1 1例高甘油三酯血症患者口服微粒化非诺贝特 2 0 0mg/d、1 0例高胆固醇血症患者口服普伐他汀 1 0mg/d治疗 4周前后和 6例正常人的LDL在体外以CuCl2 诱导氧化 ,测定LDL开始氧化的迟滞期和氧化速率。结果 (1 )LDL氧化的迟滞期 ,在高甘油三酯血症患者和高胆固醇血症患者均较正常组明显缩短 (43 8± 1 1 6 ,40 8± 1 0 7vs 70 5± 1 4 6min ,P均 <0 0 1 )。 (2 )LDL的氧化速率 ,在高甘油三酯血症患者和高胆固醇血症患者均较正常组明显增快 (0 0 36± 0 0 0 4 ,0 0 31± 0 0 1 1vs 0 0 2 0± 0 0 1 1O D /min ,P均 <0 0 5)。 (3)高甘油三酯血症患者给微粒化非诺贝特治疗后LDL氧化的迟滞期显著延长 (62 4± 5 0min,P <0 0 1 ) ,氧化速率明显减慢 (0 0 31± 0 0 0 3O D /min ,P <0 0 5)。 (4)高胆固醇血症患者于普伐他汀治疗后LDL氧化的迟滞期明显延长 (58 8± 6 1min ,P <0 0 5) ,氧化速率无显著性变化 (0 0 2 5± 0 0 0 9O D /min ,P >0 0 5)。结论 高甘油三酯血症患者和高胆固醇血症患者LDL氧化易感性增高 ,微粒化非诺贝特和普伐他汀能够降低高甘油三酯血症患?

Objective To investigate the effects of hypertriglyceridemia and hypercholesterolemia on the oxidative susceptibility of low density lipoprotein (LDL) and the effects of micronised fenofibrate and pravastatin on LDL oxidative susceptibility in hypertriglyceridemic and hypercholesterolemic patients Methods LDL was separated by a short run density gradient ultra centrifugation from the plasma of 11 hypertriglyceridemic patients before and after the treatment with micronised fenofibrate at a dose of 200 mg/d for 4 weeks 10 hypercholesterolemic patients before and after pravastatin therapy at a dose of 10 mg/d for 4 weeks and 6 healthy subjects as controls CuCl 2 (10 μmol/L) induced oxidation of LDL was used to measure the rate of LDL oxidation and the lag time required for the initiation of LDL oxidation Results (1)In terms of LDL oxidative kinetics, lag time in the hypertriglyceridemic group and hypercholesterolemic group were both shortened significantly compared with that in the controls(43 8±11 6 min, 40 8±10 7 min vs 70 5±14 6 min, P <0 01) The rate of LDL oxidation in the hypertriglyceridemic group and hypercholesterolemic group were much increased compared with that in the controls (0 036±0 004 O D /min,0 031±0 011 O D /min vs 0 020±0 011 O D /min, both P <0 05) (2)After the treatment with micronised fenofibrate in hypertriglyceridemia patients, the lag time was prolonged (62 4±5 0 min, P <0 01) and the rate of LDL oxidation slow down(0 031±0 003 O D /min, P <0 05) (3)In patients with hypercholesterolemia, the lag time was significantly prolonged(58 8±6 1 min, P <0 05), however, the rate of LDL oxidation was not slow significantly after pravastatin therapy(0 025±0 009 O D /min, P >0 05) Conclusion LDL are more susceptible to oxidative modifications both in hypertriglyceridemic or hypercholesterolemic patients The oxidative effect of LDL should be attenuated by the treatment with micronised fenofibrate or pravastatin